AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01182415
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
Trial: NCT01515137
Drug: Erlotinib plus sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Trial: NCT01515137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
Trial: NCT03962738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00554359
Drug: I5NP (a small interfering RNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV injection of experimental drug
Trial: NCT00554359
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV injection of saline
Trial: NCT03857893
Drug: pH-Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
Trial: NCT01423526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, oral administration, single administrations
Trial: NCT04074174
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
Trial: NCT02355431
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
Trial: NCT00924326
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
Trial: NCT00924326
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
Trial: NCT00509067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
Trial: NCT01155986
Drug: Placebo topical plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrogel plaster
Trial: NCT03749369
Drug: Salvadora Persica Root
RxNorm normalized name: SALVADORA PERSICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvadora Persica Gel
Trial: NCT02577614
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo after cardiopulmonary bypass
Trial: NCT00175617
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Trial: NCT03912337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once every 4 weeks. SC injection.
Trial: NCT02871778
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871778
Drug: Placebo (0.17% saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02134080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally at 4mg daily for four weeks.
Trial: NCT02261779
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01638078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, pill, once p.d., 6 weeks
Trial: NCT04183283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01466530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
Trial: NCT01386294
Drug: Universal placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
Trial: NCT01543828
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delivered via single-dose dry-powder inhaler
Trial: NCT02226952
Drug: BILN 2061 W, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02226952
Drug: BILN 2061 W, medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00073528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (which matched with lapatinib tablet)
Trial: NCT02226952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01148095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04625114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
Trial: NCT04625114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
Trial: NCT00003702
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intramuscularly
Trial: NCT00535275
Drug: Chemotherapy with platine
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
Trial: NCT01318499
Drug: Nepafenac Ophthalmic Suspension, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Trial: NCT00602095
Drug: dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg vaginal gel every 6 hours until progress
Trial: NCT00843518
Drug: LY451395
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
Trial: NCT00843518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice daily for 12 weeks
Trial: NCT00962442
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosé 5% perfusion for 14 days, intravenously
Trial: NCT02985099
Drug: SRP plus placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP followed by placebo gel placement into intrabony defect
Trial: NCT01059110
Drug: 5-Fluoro-Uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cream, one application every night, during 12 hours, for 90 days
Trial: NCT03770091
Drug: Theraworx
RxNorm normalized name: Theraworx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theraworx foam applied to skin and/or compression wrap
Trial: NCT03770091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo foam
Trial: NCT03951051
Drug: Olmetec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
Trial: NCT00458796
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00995475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01079988
Drug: Retinoids
RxNorm normalized name: Retinoids for cancer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
Trial: NCT01079988
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
Trial: NCT01079988
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
Trial: NCT01079988
Drug: Systemic corticosteroids/methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
Trial: NCT03252353
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02431897
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
Trial: NCT03044249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT02782520
Drug: Hypertonic saline (3ml/kg) fluid expansion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00279019
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
Trial: NCT00279019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
Trial: NCT00391105
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00887263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg TID
Trial: NCT00857623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, once daily
Trial: NCT04035603
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
Trial: NCT02721888
Drug: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227602
Drug: Mango polyphenolics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen mango pack will be provided (200\~400g per day).
Trial: NCT03639311
Drug: RPV LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered RPV LA (900 mg), Q2M, as intramuscular injection.
Trial: NCT03843281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s. above
Trial: NCT02767310
Drug: Rosuvastatin 20 mg film-coated tablets
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 20 mg
Trial: NCT02511353
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ivermectin.
Trial: NCT01721876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Volasertib
Trial: NCT02767310
Drug: Crestor 20 mg film-coated tablets
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 20 mg
Trial: NCT00360906
Drug: Triomar™ (omega-3 fatty acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03877536
Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
RxNorm normalized name: Genvoya 150mg-150mg-200mg-10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 tablet per day throughout study duration (96 weeks).
Trial: NCT03068260
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g orally administered postoperatively
Trial: NCT02760979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum one year after surgery
Trial: NCT00687440
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.
Trial: NCT01979536
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01979536
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01979536
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and IV
Trial: NCT03068260
Drug: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered postoperatively
Trial: NCT00528021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Only
Trial: NCT04395677
Drug: AB-106
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD
Trial: NCT02349399
Drug: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
Trial: NCT00382720
Drug: Docetaxel + Oxaliplatin + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
Trial: NCT00682448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo. Subjects will remain on placebo for 6 months.
Trial: NCT01740960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
Trial: NCT00191295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00119379
Drug: NucleomaxX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NucleomaxX 36 grams TID every other day
Trial: NCT00970697
Drug: Duoderm Hydrogel™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
Trial: NCT00709553
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 10 mg od
Trial: NCT04641299
Drug: AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Trial: NCT04641299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT00322465
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg orally, twice daily for 7 days.
Trial: NCT00322465
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
Trial: NCT00411203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03377842
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
Trial: NCT03377842
Drug: apatinib and FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
Trial: NCT03029715
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narcotics
Trial: NCT04473170
Drug: COVID-19 standard care
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UAE National Guidelines for Clinical Management and Treatment of COVID-19.
Trial: NCT03846570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (identically package) administered BID
Trial: NCT05500820
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A repeat oral dose of matching placebo once daily for 10 days.
Trial: NCT02183415
Drug: BI 1356 BS, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01814020
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00699803
Drug: T-PRED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-PRED sterile ophthalmic solution
Trial: NCT02183415
Drug: BI 1356 BS, medium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03486990
Drug: TIMP-GLIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion.
Trial: NCT00044226
Drug: ML-04A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02809131
Drug: cephalexin, or levofloxacin, or clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post operative oral antibiotics
Trial: NCT02177396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01612468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg/day subcutaneous
Trial: NCT00187096
Drug: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for additional details of treatment interventions.
Trial: NCT01767298
Drug: Valsartan/Hydrochlorothiazide
RxNorm normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration or fixed dose combination
Trial: NCT02464709
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
Trial: NCT04059783
Drug: STW5 (Iberogast®, BAY98-7411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
Trial: NCT01081678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous (under the skin) injection
Trial: NCT03755895
Drug: Kalinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will have brachytherapy detachment under Kalinox
Trial: NCT03965858
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DPI is to be administered via dry powder inhaler.
Trial: NCT00657865
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02819635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet for oral administration